Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$132.15

-0.45 (-0.34%)

, BAC

Bank of America

$24.02

-0.19 (-0.78%)

20:25
07/17/17
07/17
20:25
07/17/17
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.80... Bank of America (BAC), consensus 43c... Novartis (NVS), consensus $1.18... UnitedHealth (UNH), consensus $2.38... Goldman Sachs (GS), consensus $3.40... Lockheed Martin (LMT), consensus $3.10... Progressive (PGR), consensus 60c... Comerica (CMA), consensus $1.06... Harley-Davidson (HOG), consensus $1.39... Synovus Financial (SNV), consensus 59c... Medidata Solutions (MDSO), consensus 28c... Tile Shop (TTS), consensus 16c.

JNJ

Johnson & Johnson

$132.15

-0.45 (-0.34%)

BAC

Bank of America

$24.02

-0.19 (-0.78%)

NVS

Novartis

$83.27

0.11 (0.13%)

UNH

UnitedHealth

$186.35

-0.55 (-0.29%)

GS

Goldman Sachs

$229.26

0.66 (0.29%)

LMT

Lockheed Martin

$288.49

0.36 (0.12%)

PGR

Progressive

$45.45

-0.13 (-0.29%)

CMA

Comerica

$74.52

0.26 (0.35%)

HOG

Harley-Davidson

$52.00

0.38 (0.74%)

SNV

Synovus

$44.88

0.42 (0.94%)

MDSO

Medidata

$81.00

-0.77 (-0.94%)

TTS

Tile Shop

$20.25

0.05 (0.25%)

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 01

    Aug

  • 01

    Aug

  • 09

    Aug

  • 23

    Aug

  • 02

    Oct

  • 17

    Oct

JNJ Johnson & Johnson
$132.15

-0.45 (-0.34%)

06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.
07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
BAC Bank of America
$24.02

-0.19 (-0.78%)

04/24/17
04/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Loop Capital with analyst David Miller citing valuation following the stock hitting a 52-week high on Friday. The strength in the stock over the last nine months has appropriately priced in the company's growth rate, said Miller, who maintains a $118 price target on Disney shares. 2. Groupon (GRPN) downgraded to Underweight on lackluster ad spend at Morgan Stanley with analyst Brian Nowak saying its recent local advertiser survey indicate lackluster forward advertiser spending and believes Groupon will need to spend more in order to grow North America Local Billings, which the Street seems to be underestimating. 3. Grainger (GWW) downgraded to Market Perform from Outperform at William Blair with analyst Ryan Merkel citing a lack of confidence in the company's repricing strategy. 4. Bank of America (BAC) downgraded to Hold from Buy at Berenberg with analyst James Chappell saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15. 5. DuPont Fabros (DFT) downgraded to Hold from Buy at Stifel with analyst Matthew Heinz saying shares are fully valued and demand patterns have shifted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/17
BARD
07/11/17
NO CHANGE
BARD
Big bank set-up not great, would sell into extended rally, says Baird
Baird analyst David George does not see a great set-up for money-center banks heading into Q2 earnings. He said the trade looks crowded and he would be a seller into an extended rally. George said the risk/reward is less attractive following the sector's most recent rally as economic growth remains muted and the pace of NIM expansion may slow. George believes the biggest potential catalyst would be a gradual steepening of the yield curve and pick-up on loan growth.
04/24/17
BREN
04/24/17
DOWNGRADE
Target $22
BREN
Hold
Bank of America downgraded to Hold from Buy at Berenberg
Berenberg analyst James Chappell downgraded Bank of America to Hold saying it is time to take profits. Interest rates unlikely to rise as much as has been priced into bank equity valuations, Chappell tells investors in a research note. Further, regulation and tax reform are likely to take longer than expected and not be as beneficial for the banks as many might have hoped, the analyst adds. He upped his price target for Bank of America shares to $22 from $15.
06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
NVS Novartis
$83.27

0.11 (0.13%)

07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.
07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
UNH UnitedHealth
$186.35

-0.55 (-0.29%)

07/13/17
FBCO
07/13/17
NO CHANGE
Target $200
FBCO
Outperform
UnitedHealth price target raised to $200 from $195 at Credit Suisse
Credit Suisse analyst Scott Fidel raised his price target for UnitedHealth to $200 from $195 ahead of Q2 results. He reiterates an Outperform rating on the shares.
06/27/17
KEYB
06/27/17
DOWNGRADE
KEYB
Sector Weight
LabCorp downgraded on potential acquisition at KeyBanc
As noted earlier, KeyBanc downgraded LabCorp to Sector Weight from Overweight. Analyst Donald Hooker downgraded the stock based on his belief that the company implied that it may make an "expensive" deal to acquire a contract research organization. The analyst adds that the upcoming renewal of the company's contract with UnitedHealth (UNH) in 2H18 creates uncertainty.He expects to hear news about the deal "in coming months."
06/23/17
LEER
06/23/17
NO CHANGE
LEER
Outperform
Draft version of Senate healthcare bill better than expected, says Leerink
Leerink analyst Ana Gupte said she views the draft version of the Senate healthcare bill as better than expected, stating that stabilization of the Exchanges and risk stabilization is a direct positive for health insurers and indirect positive for facility operators. The Senate bill maintains the House bill's plan to repeal all "ObamaCare" industry fees and taxes, which is a positive for Managed Care and Medical Technology players, Gupte adds. She keeps Outperform ratings on Anthem (ANTM), UnitedHealth (UNH), Cigna (CI), Humana (HUM), WellCare (WCG), Molina Healthcare (MOH) and acute care hospital operators HCA Holdings (HCA), Tenet (THC) and LifePoint (LPNT).
06/23/17
JEFF
06/23/17
NO CHANGE
JEFF
Jefferies says healthcare rally 'appropriate' after 'toothless' AHCA rewrite
Jefferies analyst David Windley said the rally yesterday in healthcare stocks was appropriate given the "anemic" rewrite of the AHCA healthcare bill by Senate Republicans. The key changes are removal of "pay-for" taxes, a somewhat longer runway for Exchange cost-sharing reduction subsidies, and delayed Medicaid transition to per capita caps, he tells investors. Windley called Cigna (CI) "probably the safest MCO in this noise", adding that Humana (HUM) would benefit most from the proposed removal of the health insurer fee. Other publicly traded healthcare insurers include Aetna (AET), Anthem (ANTM), Centene (CNC), Health Net (HNT), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
GS Goldman Sachs
$229.26

0.66 (0.29%)

04/20/17
04/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Starbucks (SBUX) upgraded to Buy from Hold at Stifel with analyst Mark Astrachan saying he views valuation as attractive and expects multiple expansion from accelerating U.S. comparable store sales growth to at least 5%-6% for the next four quarters starting in the June quarter. The analyst said shares have underperformed consumer and restaurant peers over the past 12 months and expects outperformance to be driven by meeting comp expectations. 2. Goldman Sachs (GS) upgraded to Overweight from Neutral at Atlantic Equities with analyst Christopher Wheeler telling investors investors shares are "oversold." The analyst expects the FICC business to bounce back and made just a small reduction in estimates to account for further cost measures. 3. Lear (LEA) upgraded to Outperform from Neutral at Baird with analyst David Leiker citing its recent underperformance despite improving fundamentals and a strong global auto backdrop. Leiker raised his price target to $161 from $160 on Lear shares. 4. Discovery (DISCA) upgraded to Neutral from Sell at Citi with analyst Jason Bazinet saying he sees little chance of material downward revisions to consensus earnings estimates. The analyst views the risk/reward as more balanced at current levels and upped his price target for the shares to $30 from $27. 5. Gap (GPS) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss citing the underperformance of the shares over the past 18 months and his fieldwork which suggests stability at Old Navy. The analyst raised his price target for the shares to $24 from $21. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/02/17
NOMU
06/02/17
NO CHANGE
NOMU
Goldman Sachs, Morgan Stanley Q2 EPS estimates lowered at Nomura Instinet
Nomura Instinet analyst Steven Chubak cut his Q2 EPS estimate for Goldman Sachs (GS) to $3.50 from $4.04 and lowered his Q2 EPS estimate for Morgan Stanley (MS) to 77c from 86c. The consensus EPS estimates for Goldman and Morgan Stanley are $3.92 and 84c, respectively. Chubak says that Goldman has been hurt by "weaker trading and more pronounced (investment banking) declines," while Morgan Stanley is experiencing "softer" investment banking results and "more pronounced quarter-over-quarter" fixed income declines. He keeps a Neutral rating on Goldman and a Buy rating on Morgan stanley.
06/28/17
FBCO
06/28/17
NO CHANGE
Target $240
FBCO
Outperform
Goldman Sachs price target raised to $240 from $230 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke lowered her 2017 estimates for Goldman Sachs to reflect the current low volume/low volatility trading environment. However, assuming capital markets growth follows macroeconomic growth and the company realizes incremental operating leverage, she increased her 2018 and 2019 estimates for Goldman. Katzke increased her price target on Goldman shares to $240 from $230 and keeps an Outperform rating on the stock.
LMT Lockheed Martin
$288.49

0.36 (0.12%)

02/28/17
EVER
02/28/17
NO CHANGE
EVER
Trump defense budget hike not happening, says Evercore ISI
Evercore said President Trump's budget will not be submitted to Congress for a couple of weeks and investors should understand that any president's budget submission is inherently a political document and Congress is not bound to follow it; and that this Congress will not follow it. The firm's analyst expects a continuation of modest increases in both defense and nondefense discretionary spending agreed to on a bipartisan basis over the past four years, with any increase in defense spending likely to be small and matched by similar small increases in nondefense spending.
03/01/17
SBSH
03/01/17
DOWNGRADE
SBSH
Neutral
Northrop Grumman downgraded to Neutral from Buy at Citi
Citi analyst Jason Gursky downgraded Northrop Grumman (NOC) to Neutral saying Defense stocks are now reaching fair value. The analyst this morning also downgraded to Neutral shares of Huntington Ingalls (HII) and General Dynamics (GD). Gursky keeps Buy ratings on Harris (HRS), L3 Technologies (LLL), Lockheed Martin (LMT) and Raytheon (RTN).
04/18/17
RBCM
04/18/17
NO CHANGE
RBCM
Defense stocks should be bought on any weakness, says RBC Capital
RBC Capital analyst Matthew McConnell,recommends buying defense stocks on any weakness caused by near-term funding uncertainties. The analyst says that the impact of a government shutdown on the sector would be "minor and short-lived," while geopolitical tensions have increased. Publicly traded companies in the space include BAE Systems (BAESY), Boeing (BA), General Dynamics (GD), Lockheed Martin (LMT), Northrop Grumman (NOC), Raytheon (RTN) and United Technologies (UTX).
04/26/17
ARGS
04/26/17
NO CHANGE
ARGS
Lockheed Martin weakness creates buying opportunity, says Argus
Argus analyst John Eade says that the 3% decline in Lockheed's stock after the company missed Q1 EPS expectations creates a buying opportunity,. The analyst expects the company to benefit from GOP control in DC and he thinks that the stock's valuation is attractive. Eade keeps a Buy rating on the shares.
PGR Progressive
$45.45

-0.13 (-0.29%)

05/18/17
05/18/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Progressive (PGR) upgraded to Hold from Sell at Deutsche Bank with analyst Joshua Shanker saying his concerns over the company's margins "are not longer apt" and that sees no catalyst to the downside. 2. Shake Shack (SHAK) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan saying the valuation at current share levels is attractive given Shake Shack's "industry-leading growth trajectory. 3. CarMax (KMX) upgraded to Outperform from Neutral at Wedbush with analyst Seth Basham saying the company's CAF credit losses will probably rise less in 2017 than in 2016, reducing "the risk of a credit-driven blowout." 4. Bank of Montreal (BMO) upgraded to Buy from Neutral at Citi with analyst Ian Sealey citing the recent pullback in the shares of Canadian banks as he sees "strong" book value and dividend growth over the longer term. 5. BioLineRx (BLRX) upgraded to Buy from Hold at Maxim with analyst Jason Kolbert saying the company is now closer to being a pivotal company after announcing it will initiate a Phase 3 program for BL-8040 in stem cell mobilization later this year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/17
RAJA
07/13/17
UPGRADE
RAJA
Strong Buy
Progressive upgraded to Strong Buy from Outperform at Raymond James
07/13/17
RAJA
07/13/17
UPGRADE
RAJA
Strong Buy
Progressive upgraded on improving auto cycle profits at Raymond James
As previously reported, Raymond James upgraded Progressive to Strong Buy from Outperform and increased its price target to $52 from $45. Analyst Gregory Peters believes Progressive will continue to grow net premiums written at a double digit pace through 2017 and is well positioned to benefit from emerging smartphone technology to monitor and price for distracting driving over the next 24 months. He expects up to 15% of the personal auto business could begin to report up to 20% decline in risky driving habits over the next 18 months, resulting in improving underwriting margins.
07/13/17
07/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying Snap shares offer a "compelling risk/reward opportunity." 2. Progressive (PGR) upgraded to Strong Buy from Outperform at Raymond James with analyst Gregory Peters saying he believes Progressive will continue to grow net premiums written at a double digit pace through 2017 and is well positioned to benefit from emerging smartphone technology to monitor and price for distracting driving over the next 24 months. 3. Agilent (A) upgraded to Outperform from Market Perform at Wells Fargo. 4. Hain Celestial (HAIN) upgraded to Buy from Hold at Maxim with analyst Anthony Vendetti saying that its fiscal 2018 guidance implies a turnaround in its business while the company's reporting of its prior financials without any major restatements has removed an accounting overhang. 5. Fastenal (FAST) upgraded to Strong Buy from Outperform at Raymond James analyst Sam Darkatsh saying he thinks yesterday's selloff in Fastenal shares is entirely related to MSC Industrial's (MSM) gross margin commentary and is unwarranted. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CMA Comerica
$74.52

0.26 (0.35%)

02/17/17
JEFF
02/17/17
NO CHANGE
Target $87
JEFF
Buy
Comerica priice target raised to $87 from $74 at Jefferies
Jefferies analyst Ken Usdin raised his price target for Comerica to $87 after meeting with management and keeps a Buy rating on the shares. The company is well positioned for "solid" earnings growth and higher profitability due to benefits from rate-sensitivity, efficiency gains, and capital strength, the analyst contends.
06/09/17
06/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Zynga (ZNGA) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Brian Nowak saying the company's in-game innovation, starting with Poker, is resulting in higher engagement and monetization. 2. Citi (C) upgraded to Neutral from Sell at UBS with analyst Saul Martinez saying he sees an improved risk/reward at current share levels. Global growth "looks resilient," protectionist policies have not emerged, and the path forward for structural reforms in the U.S. "is not as clear." 3. Comerica (CMA) upgraded to Outperform from Market Perform at FBR Capital. 4. Camping World (CWH) upgraded to Buy from Neutral at Goldman Sachs with analyst David Tamberrino saying he expects growth to continue despite late-cycle concerns. 5. Humana (HUM) upgraded to Buy from Hold at Argus with analyst David Toung saying he is upbeat about its growth outlook following the termination of its merger deal with Aetna (AET). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/09/17
FBRC
06/09/17
UPGRADE
Target $79
FBRC
Outperform
Comerica upgraded to Outperform from Market Perform at FBR Capital
FBR Capital analyst Bob Ramsey upgraded Comerica to Outperform and raised his price target for the shares to $79 from $74.
06/05/17
MSCO
06/05/17
NO CHANGE
MSCO
Midcap Bank sector upgraded to In-Line at Morgan Stanley
Morgan Stanley analyst Ken Zerbe upgraded the Midcap Bank sector to In-Line from Cautious citing the group's underperformance year-to-date and better earnings from lower deposit betas. The firm's top picks are SVB Financial (SIVB), Signature Bank (SBNY), KeyBanc (KEY), and Citizens Financial (CFG). Note the analyst upgraded People's United (PBCT) and Prosperity Bancshares (PB) to Equal Weight citing valuations.
HOG Harley-Davidson
$52.00

0.38 (0.74%)

07/12/17
07/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Monsanto (MON) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying Bayer's (BAYRY) all-cash offer appears on track for year-end. The analyst views the deal failing as a "low-probability scenario" and keeps a $128 price target for the shares. 2. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 3. Kimberly-Clark (KMB) downgraded to Sell from Neutral at UBS with analyst Stephen Powers saying the stock's 11% rise year-to-date is not based on fundamentals but news flow of consolidation in the Household Products sector. 4. Harley-Davidson (HOG) downgraded to Market Perform from Outperform at Bernstein with analyst David Beckel citing his belief that "demographic shifts and a stagnating economy" will prevent demand for the company's motorcycles from growing in the U.S. for the next five years. 5. IMAX (IMAX) downgraded to Market Perform from Outperform at Barrington with analyst James Goss saying positive catalysts "might take some time to develop." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/17
RBCM
07/13/17
NO CHANGE
RBCM
Harley-Davidson acquisition of Ducati would be 'risky,' says RBC Capital
After Reuters reported that Harley-Davidson may look to buy Ducati, RBC Capital analyst Joseph Spak calls Ducati "a great brand," but says that acquiring it "could set up a culture clash" and would be "risky" for Harley-Davidson. After conducting checks with U.S. powersports dealers, Spak estimates that Harley's U.S. unit retail sales came in at -1% to +1% year-over-year. He continues to expect the sector to generate "stagnant growth over coming years" and keeps a Sector Perform rating on the name.
07/13/17
LBOW
07/13/17
NO CHANGE
LBOW
Harley-Davidson Q2 results likely to miss expectations, says Longbow
Longbow analyst David Macgregor expects Harley-Davidson's Q2 results to come in below expectations as he says his checks indicate that its U.S. retail sales fell 1%-3%. The analyst keeps a Neutral rating on the stock.
07/13/17
CLVD
07/13/17
NO CHANGE
CLVD
Neutral
Harley-Davidson checks point to sluggish demand, says Cleveland Research
Cleveland Research said its checks are pointing to sluggish demand for Harley-Davidson and the firm expects only a modest improvement in retail sales in Q2, which will likely be viewed by the market as a disappointment. The firm, which expects fiscal year shipments to miss the consensus view, keeps a Neutral rating on Harley shares.
SNV Synovus
$44.88

0.42 (0.94%)

07/17/17
RBCM
07/17/17
INITIATION
RBCM
Outperform
Synovus initiated with an Outperform at RBC Capital
RBC Capital analyst Jake Civiello expects Synovus to benefit from accelerating topline growth into 2018, increased focus on loan profitability maximization and improving operating efficiency. Target $51.
05/11/17
05/11/17
UPGRADE

Buy
Synovus upgraded to Buy at BofA/Merrill
As previously reported, BofA/Merrill upgraded Synovus to Buy from Neutral and raised its price target to $50. The firm views risk/reward as attractive given outlook for above average earnings growth and views it as an attractive M&A target for a larger bank given the attractiveness of its Southeast footprint.
03/30/17
SPHN
03/30/17
NO CHANGE
Target $64
SPHN
Overweight
TSYS could see 'a small benefit' from Cabela's sale, says Stephens
Stephens analyst Brett Huff thinks TSYS (TSS) could see "a small benefit" from the sale of Cabela's (CAB). After being delayed by regulatory approvals, The Wall Street Journal is reporting that Bass Pro would buy the retail ops, Synovus (SNV) would buy bank/co-branded credit card portfolio, and in turn selling the portfolio to Capital One (COF), he notes. The analyst points out that TSYS is Capital One's card issuing processor, and says he thinks the about 2M active cards would move to TSYS' platform. Huff reiterates an Overweight rating and $64 price target on TSYS's shares.
05/11/17
BOFA
05/11/17
UPGRADE
BOFA
Buy
Synovus upgraded to Buy from Neutral at BofA/Merrill
MDSO Medidata
$81.00

-0.77 (-0.94%)

05/01/17
JEFF
05/01/17
UPGRADE
Target $63
JEFF
Hold
Medidata upgraded to Hold from Underperform at Jefferies
Jefferies analyst David Windley upgraded Medidata Solutions to Hold citing increased confidence in the company's growth targets. Channel checks suggest competitive displacements and increasing deal size should drive sustained high-teens to 20% revenue growth, the analyst contends. He raised his price target for the shares to $63 from $47.
06/27/17
RHCO
06/27/17
NO CHANGE
RHCO
Medidata price target raised to $90 from $80 at SunTrust
SunTrust analyst Sandy Draper says that inVentiv appears to be pursuing " a much larger relationship" with Medidiata. The analyst adds that Medidata "recently signed one of its first multi-million dollar, multi-year imaging deals" in the wake of its 2Q16 acquisition of Intelmage. Draper raised his price target on Medidata to $90 from $80 and keeps a Buy rating on the stock.
06/12/17
KEYB
06/12/17
NO CHANGE
KEYB
Medidata to benefit from growth of risk-based monitoring, says KeyBanc
KeyBanc says that industry guidelines recently adopted by the EU should be a catalyst for risk-based monitoring technologies, or RBM. The firm says that Medidiata is the HCT it covers which is most exposed to RBM. It thinks that the company's revenue from RBM has reached a $50M annual run rate, while further adoption of RBM should accelerate adoption of its other SaaS tools. KeyBanc raised its price target on the stock to $84 from $83 and keeps an Overweight rating on the shares.
06/06/17
BOFA
06/06/17
INITIATION
Target $85
BOFA
Buy
Medidata initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Steven Valiquette initiated Medidata Solutions with a Buy and an $85 price target saying it has established itself as a lading provider of cloud-based clinical trial data capture with robust growth.
TTS Tile Shop
$20.25

0.05 (0.25%)

TODAY'S FREE FLY STORIES

AIV

Aimco

$44.15

-0.09 (-0.20%)

12:43
10/18/17
10/18
12:43
10/18/17
12:43
Hot Stocks
Aimco asks court to halt Airbnb activity pending final ruling on lawsuit »

Apartment Investment and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

VIAB

Viacom

$26.57

0.31 (1.18%)

, CHTR

Charter

$357.84

-4.76 (-1.31%)

12:38
10/18/17
10/18
12:38
10/18/17
12:38
Recommendations
Viacom, Charter analyst commentary  »

Viacom carriage deal…

VIAB

Viacom

$26.57

0.31 (1.18%)

CHTR

Charter

$357.84

-4.76 (-1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

CMG

Chipotle

$321.62

-7.68 (-2.33%)

12:36
10/18/17
10/18
12:36
10/18/17
12:36
Hot Stocks
Chipotle slides after analyst says sell on labor costs concerns »

Shares of Chipotle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

DYN

Dynegy

$9.53

0.085 (0.90%)

12:35
10/18/17
10/18
12:35
10/18/17
12:35
Options
Dynegy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$93.54

-1.12 (-1.18%)

12:34
10/18/17
10/18
12:34
10/18/17
12:34
Hot Stocks
BioMarin says Pegvaliase application remains on track »

BioMarin said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

  • 06

    Nov

  • 28

    Feb

BMRN

BioMarin

$93.54

-1.12 (-1.18%)

12:32
10/18/17
10/18
12:32
10/18/17
12:32
Hot Stocks
BioMarin provides update on development portfolio »

BioMarin updated the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

  • 06

    Nov

  • 28

    Feb

IBM

IBM

$160.45

13.905 (9.49%)

, ABT

Abbott

$56.00

0.9449 (1.72%)

12:30
10/18/17
10/18
12:30
10/18/17
12:30
General news
On The Fly: Top stock stories at midday »

Stocks opened sharply…

IBM

IBM

$160.45

13.905 (9.49%)

ABT

Abbott

$56.00

0.9449 (1.72%)

ANTM

Anthem

$193.45

6.19 (3.31%)

CVS

CVS Health

$74.11

1.475 (2.03%)

CREE

Cree

$29.34

0.06 (0.20%)

RXDX

Ignyta

$14.35

0.95 (7.09%)

AGN

Allergan

$188.67

-9.11 (-4.61%)

SVU

Supervalu

$17.73

-1.65 (-8.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 01

    Nov

  • 06

    Nov

  • 06

    Nov

  • 15

    Nov

  • 12

    Dec

BMRN

BioMarin

$93.54

-1.12 (-1.18%)

12:29
10/18/17
10/18
12:29
10/18/17
12:29
Earnings
BioMarin sees 2017 product revenue at mid-point of guidance »

BioMarin said that at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

  • 06

    Nov

  • 28

    Feb

EQT

EQT Corporation

$62.94

-0.3799 (-0.60%)

12:25
10/18/17
10/18
12:25
10/18/17
12:25
Options
EQT Corporation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 14

    Nov

NLSN

Nielsen

$41.06

1.06 (2.65%)

, LGF

Use LGF.A, LGF.B

12:20
10/18/17
10/18
12:20
10/18/17
12:20
Hot Stocks
Nielsen to independently measure subscription-based streaming content. »

Nielsen announced that…

NLSN

Nielsen

$41.06

1.06 (2.65%)

LGF

Use LGF.A, LGF.B

DIS

Disney

$97.64

-0.7161 (-0.73%)

TWX

Time Warner

$101.12

-0.34 (-0.34%)

NFLX

Netflix

$199.48

-3.2 (-1.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 09

    Nov

$NSD

NASDAQ Market Internals

12:17
10/18/17
10/18
12:17
10/18/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
10/18/17
10/18
12:16
10/18/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOBL

MobileIron

$3.80

-0.1 (-2.56%)

12:10
10/18/17
10/18
12:10
10/18/17
12:10
Downgrade
MobileIron rating change  »

MobileIron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$7.08

0.07 (1.00%)

12:10
10/18/17
10/18
12:10
10/18/17
12:10
Options
Far downside put buyer in MBIA opens a notable new position »

Far downside put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOBL

MobileIron

$3.80

-0.1 (-2.56%)

12:07
10/18/17
10/18
12:07
10/18/17
12:07
Downgrade
MobileIron rating change  »

MobileIron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

12:06
10/18/17
10/18
12:06
10/18/17
12:06
Technical Analysis
Technical Earnings Preview: Steel Dynamics has a potential bullish pattern »

On a very long-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

DANOY

Danone

$16.67

0.3 (1.83%)

12:05
10/18/17
10/18
12:05
10/18/17
12:05
Hot Stocks
Danone names Emmanuel Faber as both Chairman and CEO »

Danone announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$199.48

-3.2 (-1.58%)

12:00
10/18/17
10/18
12:00
10/18/17
12:00
Options
Large four-way option spread in Netflix as shares slump for a second day »

Large four-way option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

12:00
10/18/17
10/18
12:00
10/18/17
12:00
General news
Treasury Action: TIPS are weaker »

Treasury Action: TIPS are…

ADBE

Adobe

$150.38

-0.08 (-0.05%)

11:55
10/18/17
10/18
11:55
10/18/17
11:55
Hot Stocks
Adobe announces acquisition of KyleBrush.com; terms not disclosed »

Adobe announces in a blog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 06

    Nov

GMLP

Golar LNG Partners

$22.98

-0.08 (-0.35%)

11:50
10/18/17
10/18
11:50
10/18/17
11:50
Options
Notable call write in Golar LNG Partners »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
10/18/17
10/18
11:50
10/18/17
11:50
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

IPXL

Impax

$19.30

-0.65 (-3.26%)

11:45
10/18/17
10/18
11:45
10/18/17
11:45
Conference/Events
Impax management to meet with Deutsche Bank »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 09

    Nov

BITCOIN

Bitcoin

11:44
10/18/17
10/18
11:44
10/18/17
11:44
Hot Stocks
Bitcoin falls after release of CFTC report on virtual currencies »

The U.S. Commodity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$37.49

-0.28 (-0.74%)

, SHOP

Shopify

$98.14

1.93 (2.01%)

11:41
10/18/17
10/18
11:41
10/18/17
11:41
Earnings
On The Fly: What to watch in eBay earnings report »

eBay (EBAY) is scheduled…

EBAY

eBay

$37.49

-0.28 (-0.74%)

SHOP

Shopify

$98.14

1.93 (2.01%)

AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 14

    Nov

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.